Business
UPDATE – Skye Bioscience Reports First Quarter 2026 Financial Results and Business Update
CBeyond™ Expansion Study (Part C) initiated; Cohort Review Committee review scheduled for May 18, 2026, to evaluate available safety data and potential progression to Cohort 2 SAN DIEGO, May 12, 2026 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (Nasdaq: SKYE) (“Skye” or the “Company”), a clinical stage biotechnology company developing next-generation molecules that modulate G-protein-coupled receptors to treat obesity, overweight, and related conditions, today reported financial results for the fir
About this update from Skye Bioscience, Inc.
[{"type":"image","alt":"Skye Bioscience, Inc.","displaySize":"","headline":null,"caption":"Skye Bioscience, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":141,"url":"https://media.zenfs.com/en/globenewswire.com/90c497d694309d41a1d6fa12ddb2a61c"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/6bcG37NNd4YMX6lS8CZe5Q--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE5Nw--/https://media.zenfs.com/en/globenewswire.com/90c497d694309d41a1d6fa12ddb2a61c","width":300,"height":141},"resize_sm":{"url":"https://s.yimg.com/ny/api/res/1.2/6bcG37NNd4YMX6lS8CZe5Q--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE5Nw--/https://media.zenfs.com/en/globenewswire.com/90c497d694309d41a1d6fa12ddb2a61c","width":300,"height":141}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"CBeyond™ Expansion Study (Part C) initiated; Cohort Review Committee review scheduled for May 18, 2026, to evaluate available safety data and potential progression to Cohort 2","length":175,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":175,"olType":false},{"type":"text","content":"SAN DIEGO, May 12, 2026 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (Nasdaq: SKYE) (“Skye” or the “Company”), a clinical stage biotechnology company developing next-generation molecules that modulate G-protein-coupled receptors to treat obesity, overweight, and related conditions, today reported financial results for the first quarter ended March 31, 2026, along with recent business updates and anticipated milestones.","length":419,"tagName":"p"},{"type":"text","content":"“Since our March update, execution has focused on turning CBeyond into a Phase 2b-ready development program,” said Punit Dhillon, President & CEO of Skye. “We have now initiated enrollment of Cohort 1 of the CBeyond Expansion Study, executed the compatibility and in-use study with ENHANZE to support a practical high-volume subcutaneous approach, and engaged external development advisors to help pressure-test our target product profile, dose-selection rationale and Phase 2b trial design. Our objective in 2026 remains focused on defining the dose and exposure that can support a larger Phase 2b study evaluating nimacimab as a complementary add-on approach for GLP-1-experienced patients.”","length":697,"tagName":"p"},{"type":"text","content":"Business and Clinical Highlights ","length":32,"tagName":"p"}...